COX-2: A target for colon cancer prevention

Annual Review of Pharmacology and Toxicology

Volumn 42, Issue , 2002, Pages 55-80

  Marnett, Lawrence J ^a   DuBois, Raymond N ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer; Cyclooxygenase; NSAIDs; Prevention; Prostaglandins

Indexed keywords

5 BROMO 2 (4 FLUOROPHENYL) 3 (4 METHYLSULFONYLPHENYL)THIOPHENE; ACETYLSALICYLIC ACID; ARACHIDONIC ACID; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; ETODOLAC; ETONCOXIB; IBUPROFEN; INDOMETACIN; KETOPROFEN; KETOROLAC; LM 4111; MECLOFENAMIC ACID; MEFENAMIC ACID; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NABUMETONE; NAPROXEN; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; OXAPROZIN; PIROXICAM; PROSTAGLANDIN G2; PROSTAGLANDIN H2; PROSTAGLANDIN SYNTHASE; ROFECOXIB; SALICYLIC ACID DERIVATIVE; SULINDAC SULFIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALDECOXIB; ZOMEPIRAC;

ADENOMATOUS POLYP; BIOCHEMISTRY; CANCER PREVENTION; CHEMOPROPHYLAXIS; COLON CANCER; DRUG APPROVAL; DRUG EFFICACY; ENZYME ANALYSIS; ENZYME BINDING; FOOD AND DRUG ADMINISTRATION; FUTUROLOGY; GENE SEQUENCE; GENE TARGETING; GOVERNMENT; HUMAN; LIFESTYLE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; PUBLIC HEALTH; REVIEW;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTICARCINOGENIC AGENTS; COLONIC NEOPLASMS; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; HUMANS; ISOENZYMES; MEMBRANE PROTEINS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES;

EID: 0036169389     PISSN: 03621642     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.pharmtox.42.082301.164620     Document Type: Review

References (140)

1. History of aspirin and its mechanism of action
2. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs
3. 1
4. Prostaglandin hydroperoxidase, an integral part of prostaglandin endoperoxide synthetase from bovine vesicular gland microsomes
5. Quantitative studies of hydroperoxide reduction by prostaglandin H synthase
6. Co-oxygenation of organic substrates by the prostaglandin synthetase of sheep vesicular gland
7. Prostaglandin H synthase and xenobiotic oxidation
8. Enzymes in the biosynthesis and catabolism of the eicosanoids: Prostaglandins, thromboxanes, leukotrienes and hydroxy fatty acids
9. Roles of prostanoids revealed from studies using mice lacking specific prostanoid receptors
10. Prostaglandin E receptors and the kidney
11. Prostaglandin D2 selectively induces chemotaxis in T helper type 2 cells, eosinophils, and basophils via seven-transmembrane receptor CRTH2
12. Role of the prostaglandin E receptor subtype EP1 in colon carcinogenesis
13. 2 increases growth and motility of colorectal carcinoma cells
14. 2 is a mediator of cyclooxygenase-2-dependent endothelial migration and angiogenesis
15. Peroxisome proliferator-activated receptors: A nuclear receptor signaling pathway in lipid physiology
16. Differential expression and activation of a family of murine peroxisome proliferator-activated receptors
17. 2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation
18. 2 is a ligand for the adipocyte determination factor PPAR gamma
19. Cyclo-oxygenase-2-derived prostacyclin mediates embryo implantation in the mouse via PPARdelta
20. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta
21. PPARdelta is an APC-regulated target of nonsteroidal antiinflammatory drugs
22. Prostacyclin-mediated activation of peroxisome proliferator-activated receptor delta in colorectal cancer
23. Aspirin and the potential role of prostaglandins in colon cancer
24. Colorectal cancer risk, chronic illnesses, operations, and medications: Case control results from the Melbourne Colorectal Cancer Study
25. Aspirin use and reduced risk of fatal colon cancer
26. Cancer research. Anti-inflammatories inhibit cancer growth-but how?
27. The role of nonsteroidal antiinflammatory drugs in colorectal cancer prevention
28. Aspirin and the risk of colorectal cancer in women
29. Colorectal cancer and nonsteroidal antiinflammatory drugs
30. Use of nonsteroidal antiinflammatory drugs and incidence of colorectal cancer: A population-based study
31. Low dose aspirin and incidence of colorectal tumors in a randomized trial
32. Nonsteroidal anti-inflammatory drugs and cancer prevention
33. APC mutations occur early during colorectal tumorigenesis
34. Sulindac for polyposis of the colon
35. Sulindac for polyposis of colon
36. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis
37. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis
38. Primary structure of prostaglandin G/H synthase from sheep vesicular gland determined from the complementary DNA sequence
39. Isolation and characterization of the complementary DNA for sheep seminal vesicle prostaglandin endoperoxide synthase (cyclooxygenase)
40. Primary structure of sheep prostaglandin endoperoxide synthase deduced from cDNA sequence
41. Cloning of human gene encoding prostaglandin endoperoxide synthase and primary structure of the enzyme
42. Differentiation of monocytoid THP-1 cells with phorbol ester induces expression of prostaglandin endoperoxide synthase-1 (COX-1)
43. 2 synthase-1
44. Epidermal growth factor stimulates prostaglandin biosynthesis by canine kidney (MDCK) cells
45. Prostaglandin endoperoxide synthase: Regulation of enzyme expression
46. Mechanism of enhanced fibroblast arachidonic acid metabolism by mononuclear cell factor
47. Regulation of fibroblast cyclooxygenase synthesis by interleukin-1
48. Temporal and pharmacological division of fibroblast cyclooxygenase expression into transcriptional and translational phases
49. v-src-transformed 3T3 fibroblasts
50. Identification of a cyclooxygenase-related gene and its potential role in prostaglandin formation
51. 2 synthase (cyclooxygenase) in human monocytes
52. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing
53. TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue
54. cDNA cloning and functional activity of a glucocorticoid-regulated inflammatory cyclooxygenase
55. Human cyclooxygenase-2 cDNA
56. Structure of the mitogen-inducible TIS10 gene and demonstration that the TIS10-encoded protein is a functional prostaglandin G/H synthase
57. Cyclooxygenases: Structural, cellular, and molecular biology
58. Flexibility of the NSAID binding site in the structure of human cyclooxygenase-2
59. Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents
60. Comparison of the peroxidase activity of hemeproteins and cytochrome P450
61. Spectral properties of the higher oxidation states of prostaglandin H synthase
62. 2
63. Substrate-induced free radicals in prostaglandin H synthase
64. Tyrosine 385 of prostaglandin endoperoxide synthase is required for cyclooxygenase catalysis
65. Acetylation of prostaglandin endoperoxide synthetase with acetylsalicylic acid
66. The productive conformation of arachidonic acid bound to prostaglandin synthase
67. The binding of arachidonic acid in the cyclooxygenase active site of mouse prostaglandin endoperoxide synthase-2 (COX-2): A putative L-shaped binding conformation utilizing the top channel region
68. 2 synthase cyclooxygenase active site
69. Structural requirements for time-dependent inhibition of prostaglandin biosynthesis by antiinflammatory drugs
70. Mechanism of selective inhibition of the inducible isoform of prostaglandin G/H synthase
71. Kinetic basis for selective inhibition of cyclooxygenases
72. Fluorescence quenching analysis of the association and dissociation of a diaryheterocycle to cyclooxygenase-1 and cyclooxygenase-2: The dynamic basis of cyclooxygenase-2 selectivity
73. Mechanism of selective inhibition of the inducible isoform of prostaglandin G/H synthase
74. The mechanism of the effect of aspirin on human platelets I. Acetylation of a particulate fraction protein
75. Aspirin-like molecules that covalently inactivate cyclooxgyenase-2
76. 2 synthase
77. Arginine 120 of prostaglandin G/H synthase-1 is required for the inhibition by nonsteroidal anti-inflammatory drugs containing a carboxylic acid moiety
78. Tyrosine 385 is critical for acetylation of cyclooxygenase-2 by aspirin
79. A serum- and glucocorticoid-regulated 4-kilobase mRNA encodes a cyclooxygenase-related protein
80. Characterization of prostaglandin G/H synthase 1 and 2 in rat, dog, monkey, and human gastrointestinal tracts
81. Distribution of COX-1 and COX-2 in normal and inflamed tissues
82. Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic
83. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: The CLASS study: A randomized controlled trial. Celecoxib Long-Term Arthritis Safety Study
84. Do cyclooxygenase-2 inhibitors provide benefits similar to those of traditional nonsteroidal anti-inflammatory drugs, with less gastrointestinal toxicity?
85. Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other nonsteroidal anti-inflammatory drugs
86. Antiinflammatory and safety profile of DuP 697, a novel orally effective prostaglandin synthesis inhibitor
87. NS-398, a new anti-inflammatory agent, selectively inhibits prostaglandin G/H synthase/cyclooxygenase (COX-2) activity in vitro
88. Selective cyclooxygenase-2 inhibitors
89. Selective inhibitors of cyclooxygenase-2 (COX-2)
90. Novel 1,2-diarylcyclobutenes: Selective and orally active COX-2 inhibitors
91. Selective cyclooxygenase inhibitors: Novel 4-spiro 1,2-diarylcyclopentenes are potent and orally active COX-2 inhibitors
92. A single amino acid difference between cyclooxygenase-1 (COX-1) and -2 (COX-2) reverses the selectivity of COX-2 specific inhibitors
93. 509 in time-dependent inhibition of human prostaglandin H synthase-2 cyclooxygenase activity by isoform-selective agents
94. 523→Val mutation
95. 509 in time-dependent inhibition of human prostaglandin H synthase-2 cyclooxygenase activity by isoform-selective agents
96. Effects of celecoxib, a novel cyclooxygenase-2 inhibitor, on platelet function in healthy adults: A randomized, controlled trial
97. Pharmacokinetics, COX-2 specificity, and tolerability of supratherapeutic doses of rofecoxib in humans
98. Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: Identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide (SC-58635, Celecoxib)
99. Rofecoxib [Vioxx, MK-0966; 4-(4′-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: A potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles
100. The discovery of rofecoxib, [MK 966, Vioxx(R), 4-(4′-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2 inhibitor
101. Clinical pharmacokinetics and pharmacodynamics of celecoxib: A selective cyclo-oxygenase-2 inhibitor
102. Update on clinical developments with celecoxib, a new specific COX-2 inhibitor: What can we expect?
103. Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium: Results of a one-year, randomized, clinical trial in patients with osteoarthritis of the knee and hip
104. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: The human pharmacology of a selective inhibitor of COX-2
105. Metabolism and excretion of [(14)C]celecoxib in healthy male volunteers
106. Major role of human liver microsomal cytochrome P450 2C9 (CYP2C9) in the oxidative metabolism of celecoxib, a novel cyclooxygenase-II inhibitor
107. Prostaglandin levels in normal and transformed baby hamster kidney fibroblasts
108. Modulation of arachidonic acid metabolism by Rous sarcoma virus
109. Prostaglandins from tumours of human large bowel
110. Cloning and characterization of a growth factor-inducible cyclooxygenase gene from rat intestinal epithelial cells
111. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas
112. Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer
113. Expression of cyclooxygenase-1 and -2 in human colorectal cancer
114. Localization of cyclooxygenase-2 in human sporadic colorectal adenomas
115. Increased cyclooxygenase-2 levels in carcinogen-induced rat colonic tumors
116. Elevated cyclooxygenase-2 levels in Min mouse adenomas
117. Δ716 knockout mice by inhibition of cyclooxygenase 2 (COX-2)
118. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2
119. Min mouse model by the nonsteroidal anti-inflammatory drug piroxicam
120. Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis
121. Evaluation of cyclooxygenase-2 inhibitor for potential chemopreventive properties in colon carcinogenesis
122. Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis
123. Chemopreventive efficacy of combined piroxicam and difluoromethylornithine treatment of Apc mutant Min mouse adenomas, and selective toxicity against Apc mutant embryos
124. 2 in human colon cancer cells
125. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis
126. Cyclooxygenase regulates angiogenesis induced by colon cancer cells
127. Cyclooxygenase inhibitors suppress angiogenesis and reduce tumor growth in vivo
128. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors
129. Host cyclooxygenase-2 modulates carcinoma growth
130. Inhibition of haematogenous metastasis of colon cancer in mice by a selective COX-2 inhibitor
131. Preferential enhancement of tumor radioresponse by a cyclooxygenase-2 inhibitor
132. Antineoplastic drugs sulindac sulfide and sulfone inhibit cell growth by inducing apoptosis
133. Apoptosis primarily accounts for the growth-inhibitory properties of sulindac metabolites and involves a mechanism that is independent of cyclooxygenase inhibition, cell cycle arrest, and p53 induction
134. Genetic disruption of PPARdelta decreases the tumorigenicity of human colon cancer cells
135. Controlled trial of high- versus low-dose aspirin treatment after percutaneous transluminal angioplasty in patients with peripheral vascular disease
136. NSAIDs, gastrointestinal injury, and cytoprotection
137. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis
138. Nonsteroidal anti-inflammatory drugs and life threatening complications of peptic ulceration
139. Excess costs from gastrointestinal disease associated with nonsteroidal anti-inflammatory drugs
140. Genetic testing for cancer predisposition